122 related articles for article (PubMed ID: 20524880)
1. Experience with biologics for psoriasis in daily practice: rotational therapy is required.
Saccomani C; Penz S; Guerre-Schmidt R; Pelletier F; Puzenat E; Riou-Gotta MO; Humbert P; Aubin F
J Dermatolog Treat; 2011 Jun; 22(3):151-2. PubMed ID: 20524880
[No Abstract] [Full Text] [Related]
2. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
4. Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.
Saraceno R; Scotto G; Chiricozzi A; Chimenti S
Acta Derm Venereol; 2009; 89(4):412-3. PubMed ID: 19688158
[No Abstract] [Full Text] [Related]
5. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
Strober BE
Arch Dermatol; 2004 Mar; 140(3):366. PubMed ID: 15023789
[No Abstract] [Full Text] [Related]
6. A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.
Kitamura G; Mehr N; Anderson N; Sirichotiratana M
Dermatol Online J; 2009 Feb; 15(2):11. PubMed ID: 19336028
[TBL] [Abstract][Full Text] [Related]
7. Experience with biologics for psoriasis in daily practice: switching is worth a try.
Lecluse LL; de Groot M; Bos JD; Spuls PI
Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
[No Abstract] [Full Text] [Related]
8. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.
Adişen E; Karaca F; Gürer MA
Clin Exp Dermatol; 2008 Mar; 33(2):164-6. PubMed ID: 18257837
[TBL] [Abstract][Full Text] [Related]
9. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.
Kluger N; Girard C; Guillot B; Bessis D
Acta Derm Venereol; 2009; 89(3):332-4. PubMed ID: 19479148
[No Abstract] [Full Text] [Related]
10. Biological therapy and nail psoriasis.
Lawry M
Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy for psoriasis: a brief history, II.
Tutrone WD; Kagen MH; Barbagallo J; Weinberg JM
Cutis; 2001 Dec; 68(6):367-72. PubMed ID: 11775769
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis.
Antoniou C; Dessinioti C; Vergou T; Stratigos AJ; Avgerinou G; Kostaki M; Katsambas A
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1413-20. PubMed ID: 20384690
[TBL] [Abstract][Full Text] [Related]
13. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
[TBL] [Abstract][Full Text] [Related]
14. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
Haitz KA; Kalb RE
J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
[TBL] [Abstract][Full Text] [Related]
16. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
18. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
